학술논문
MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
Document Type
Report
Author
Source
Pharmacogenomics and Personalized Medicine. Annual, 2017, Vol. 10, p69, 10 p.
Subject
Language
English
ISSN
1178-7066
Abstract
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes. Keywords: MTHFR, methotrexate, toxicity, outcome, C677T, A1298C
Introduction Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, representing ~30% of all childhood malignancies. (1,2) Survival rates have increased dramatically over the last years [...]
Introduction Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, representing ~30% of all childhood malignancies. (1,2) Survival rates have increased dramatically over the last years [...]